Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. 1996

K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
Department of Pediatrics, University Hospital Malmo, Sweden.

The spontaneous growth process in Turner's syndrome is characterized by a progressive decline in height velocity during childhood and no pubertal growth spurt. Therefore, therapy aimed at improving height during childhood as well as increasing final height is desirable for most girls with Turner's syndrome. Forty-five girls with Turner's syndrome, 9-16 yr of age (mean age, 12.2 yr), were allocated to three study groups. Group 1 (n = 13) was initially treated with oxandrolone alone; after 1 yr of treatment, GH without (group 1a; n = 6) or with (group 1b; n = 7) ethinyl estradiol was added. Group 2 (n = 17) was treated with GH plus oxandrolone. Group 3 (n = 15) was treated with GH, oxandrolone, and ethinyl estradiol. The dosage were: GH, 0.1 IU/kg.day; oxandrolone, 0.05 mg/kg.day; and ethinyl estradiol, 100 ng/kg.day. A height of 150 cm or more was achieved in 61%, 75%, and 60% of the girls in groups 1, 2, and 3, respectively. The most impressive increase in height was seen in group 2. In this group the mean final height was 154.2 cm (SD = 6.6), which is equivalent to a mean net gain of 8.5 cm (SD = 4.6) over the projected final height. In group 3, in which ethinyl estradiol was included from the start of therapy, the initially good height velocity decelerated after 1-2 yr of treatment. Their mean final height was 151.1 (SD = 4.6) cm, equivalent to a mean net gain of 3.0 cm (SD = 3.8). A similar growth-decelerating effect of ethinyl estradiol was seen in group 1b. We conclude that in girls with Turner's syndrome who are older than 9 yr of age, treatment with GH in combination with oxandrolone results in significant growth acceleration, imitating that in normal puberty, leading to a more favorable height during childhood. This mode of treatment also results in a significantly increased final height, permitting a great number of the girls to attain a final height of more than 150 cm. However, early addition of estrogen decelerates the height velocity and reduces the gain in height.

UI MeSH Term Description Entries
D010074 Oxandrolone A synthetic hormone with anabolic and androgenic properties. Anavar,Oxandrin,SC-11585,SC 11585,SC11585
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000365 Age Determination by Skeleton Establishment of the age of an individual by examination of their skeletal structure. Bone Age Measurement,Skeletal Age Measurement,Skeletal Maturation Index,Age Measurement, Bone,Age Measurement, Skeletal,Age Measurements, Bone,Age Measurements, Skeletal,Bone Age Measurements,Index, Skeletal Maturation,Indices, Skeletal Maturation,Maturation Index, Skeletal,Maturation Indices, Skeletal,Measurement, Bone Age,Measurement, Skeletal Age,Measurements, Bone Age,Measurements, Skeletal Age,Skeletal Age Measurements,Skeletal Maturation Indices
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin
D014424 Turner Syndrome A syndrome of defective gonadal development in phenotypic females associated with the karyotype 45,X (or 45,XO). Patients generally are of short stature with undifferentiated GONADS (streak gonads), SEXUAL INFANTILISM, HYPOGONADISM, webbing of the neck, cubitus valgus, elevated GONADOTROPINS, decreased ESTRADIOL level in blood, and CONGENITAL HEART DEFECTS. NOONAN SYNDROME (also called Pseudo-Turner Syndrome and Male Turner Syndrome) resembles this disorder; however, it occurs in males and females with a normal karyotype and is inherited as an autosomal dominant. Bonnevie-Ullrich Syndrome,Gonadal Dysgenesis, 45,X,Gonadal Dysgenesis, XO,Monosomy X,Status Bonnevie-Ullrich,Turner's Syndrome,Ullrich-Turner Syndrome,Bonnevie Ullrich Syndrome,Status Bonnevie Ullrich,Syndrome, Ullrich-Turner,Turners Syndrome,Ullrich Turner Syndrome,XO Gonadal Dysgenesis

Related Publications

K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
December 1991, Acta paediatrica Scandinavica,
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
January 1990, Acta paediatrica Scandinavica,
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
September 1984, Acta paediatrica Scandinavica,
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
January 1999, Archives of disease in childhood,
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
January 2000, Medicina,
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
January 1999, Hormone research,
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
April 2006, The Journal of clinical endocrinology and metabolism,
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
January 2011, Hormone research in paediatrics,
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
May 1995, Acta paediatrica (Oslo, Norway : 1992),
K O Nilsson, and K Albertsson-Wikland, and J Alm, and S Aronson, and J Gustafsson, and L Hagenäs, and A Häger, and S A Ivarsson, and J Karlberg, and B Kriström, and C Marcus, and C Moell, and M Ritzen, and T Tuvemo, and C Wattsgård, and U Westgren, and O Westphal, and J Aman
April 1994, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
Copied contents to your clipboard!